Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Quintiles IMS Holdings Inc    Q

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/14/2017 09/15/2017 09/18/2017 09/19/2017 09/20/2017 Date
95.45(c) 94.47(c) 95.07(c) 95(c) 94.64 Last
1 326 993 5 759 583 2 055 918 1 086 208 1 510 201 Volume
-1.16% -1.03% +0.64% -0.07% -0.38% Change
More quotes
Financials ($)
Sales 2017 8 031 M
EBIT 2017 1 680 M
Net income 2017 432 M
Debt 2017 5 999 M
Yield 2017 -
Sales 2018 8 518 M
EBIT 2018 1 765 M
Net income 2018 621 M
Debt 2018 6 509 M
Yield 2018 -
P/E ratio 2017 51,24
P/E ratio 2018 34,67
EV / Sales2017 3,29x
EV / Sales2018 3,16x
Capitalization 20 435 M
More Financials
Company
Quintiles IMS Holdings, Inc. is a biotechnology company, which engages in healthcare development in the provision of professional services, information technology, and partnering solutions to the pharmaceutical services and healthcare industries.The company was founded by Dennis Gillings and Gary... 
More about the company
Surperformance© ratings of Quintiles IMS Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on QUINTILES IMS HOLDINGS INC
09/19 QUINTILES IMS HOLDINGS, INC. : Entry into a Material Definitive Agreement, Creat..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/15 QUINTILES IMS : QuintilesIMS Announces Pricing of Secondary Public Offering
09/14 QUINTILES IMS : QuintilesIMS Announces Launch of Secondary Public Offering and R..
09/11 QUINTILES IMS HOLDINGS, INC. (NYSE : Q) Files An 8-K Entry into a Material Defin..
09/11 QUINTILES IMS HOLDINGS, INC. : Entry into a Material Definitive Agreement, Other..
09/11 QUINTILES IMS : QuintilesIMS Announces Pricing on Offering of Senior Notes
09/11 QUINTILES IMS HOLDINGS, INC. (NYSE : Q) Files An 8-K Financial Statements and Ex..
09/11 QUINTILES IMS : QuintilesIMS Announces Offering of Senior Notes, Redemption of E..
08/22 QUINTILES IMS HOLDINGS INC : Earnings Review and Free Research Report: Quintiles..
More news
Sector news : Biotechnology & Medical Research - NEC
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
08/29DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/19+Initiations 9/19: $ACIA $ATNX $CERN $CVS $DWDP $ESNC $GPOR $HPP $INTU $MDRX ..
1
09/19Quintiles Transitional Holdings initiated by Royal Bank Of Canada at outperfo.. 
09/19SG Americas Securities LLC Sells 13,395 Shares of Quintiles Transitional Hold.. 
09/18Quintiles Transitional Holdings's PT raised by Argus to $104.00. buy rating. .. 
09/18Monday's Top Analyst Upgrades & Downgrades $ASML $GE $HUBS $INFY $TEVA $..
1
More tweets
Qtime:79
News from SeekingAlpha
09/15 Quintiles IMS prices stock offering at $95.25; shares down 1% premarket
09/09 VEEVA SYSTEMS : A Healthy Buy
08/24 DowDuPont heading to DJIA; Q, SBAC up on other index moves
08/23 Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2017 Update
08/22 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2017 Updat..
Chart QUINTILES IMS HOLDINGS INC
Duration : Period :
Quintiles IMS Holdings Inc Technical Analysis Chart | Q | US74876Y1010 | 4-Traders
Technical analysis trends QUINTILES IMS HOLDINGS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 99,0 $
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Ari Bousbib Chairman, President & Chief Executive Officer
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jonathan J. Coslet Director
Michael J. Evanisko Director
Sector and Competitors
1st jan.Capitalization (M$)
QUINTILES IMS HOLDINGS INC24.22%20 435
INCYTE CORPORATION18.83%24 941
LONZA GROUP54.86%19 540
CELLTRION, INC.--.--%15 038
ALKERMES PLC-6.41%7 993
SEATTLE GENETICS, INC.1.93%7 565